Yamanaka Takeharu, Matsumoto Shigemi, Teramukai Satoshi, Ishiwata Ryota, Nagai Yoji, Fukushima Masanori
Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka, Japan.
Oncology. 2007;73(3-4):215-20. doi: 10.1159/000127412. Epub 2008 Apr 17.
In cancer patients, the balance between neutrophil (N) and lymphocyte (L) cell counts fluctuates with advancing disease. The objective of our study was to determine the prognostic implications of the N/L ratio in the peripheral blood of gastric cancer patients.
Study participants were identified from a prospective cohort of patients with advanced gastric cancer in Japan (n = 1,220).
The median baseline N/L was 2.58 (range, 0.63-12.7). Univariate analysis revealed that patients with an N/L > pr =2.5 (n = 644) had a significantly poorer prognosis than those with an N/L <2.5 (n = 576; log rank test, p = 0.019 x 10(-12)). The median survival times for these two groups were 239 (95% confidence interval, CI, 217-251 days) and 363 days (95% CI, 334-406 days), respectively, while the 1-year survival rates were 30 (95% CI, 26-34%) and 50% (95% CI, 45-54%), respectively. A multivariate Cox model established a significant relationship between the N/L ratio and survival (adjusted hazard ratio = 1.52; 95% CI, 1.32-1.75; p = 0.077 x 10(-8)).
These results suggest that the N/L ratio is an independent prognostic factor in advanced gastric cancer. Measurement of this ratio may serve as a clinically accessible and useful biomarker for patient survival.
在癌症患者中,中性粒细胞(N)与淋巴细胞(L)计数之间的平衡会随着疾病进展而波动。我们研究的目的是确定胃癌患者外周血中N/L比值的预后意义。
研究参与者来自日本一个晚期胃癌患者的前瞻性队列(n = 1220)。
基线N/L的中位数为2.58(范围为0.63 - 12.7)。单因素分析显示,N/L>2.5的患者(n = 644)预后明显差于N/L<2.5的患者(n = 576;对数秩检验,p = 0.019×10⁻¹²)。这两组的中位生存时间分别为239天(95%置信区间,CI,217 - 251天)和363天(95%CI,334 - 406天),而1年生存率分别为30%(95%CI,26 - 34%)和50%(95%CI,45 - 54%)。多因素Cox模型确定了N/L比值与生存之间的显著关系(调整后风险比 = 1.52;95%CI,1.32 - 1.75;p = 0.077×10⁻⁸)。
这些结果表明,N/L比值是晚期胃癌的一个独立预后因素。该比值的测量可作为一种临床上可获取且有用的患者生存生物标志物。